Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00608322 · ClinicalTrials.gov registry record · Phase 3
Randomized Trial of Inhaled Nitric Oxide to Augment Tissue Perfusion in Sepsis
A Phase 3 study, sponsored by National Institute of General Medical Sciences (NIGMS).
- Completed
- Registry status
- Phase 3
- Development phase
- 49
- Enrollment target
NCT00608322: Completed Phase 3 study, sponsored by National Institute of General Medical Sciences (NIGMS).
NCT00608322 is a Phase 3 study that has completed, run by National Institute of General Medical Sciences (NIGMS). The registered enrollment target is 49 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00608322, a Phase 3 study, has completed, sponsored by National Institute of General Medical Sciences (NIGMS).
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 49 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether inhaled nitric oxide is an effective treatment for microcirculatory dysfunction and acute organ system failure in the early stage of sepsis therapy.
Interventions
- DRUG Inhaled nitric oxide
- OTHER Sham inhaled nitric oxide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2009-08 |
| Est. Completion | 2013-04 |
| Phase | Phase 3 |
What the finished NCT00608322 record still lists
NCT00608322 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 49 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (94% lower).
The record links to 0 conditions, and to 2 interventions - of which Inhaled nitric oxide is the first listed.
NCT00608322 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00608322 about?
NCT00608322 is a clinical study titled "Randomized Trial of Inhaled Nitric Oxide to Augment Tissue Perfusion in Sepsis". The purpose of this study is to determine whether inhaled nitric oxide is an effective treatment for microcirculatory dysfunction and acute organ system failure in the early stage of sepsis therapy.
What is the current status of trial NCT00608322?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 49 participants. The study started on 2009-08. Estimated completion is 2013-04.
What interventions are being tested in trial NCT00608322?
The interventions under investigation include: Inhaled nitric oxide (DRUG), Sham inhaled nitric oxide (OTHER).
Who is sponsoring clinical trial NCT00608322?
This trial is sponsored by National Institute of General Medical Sciences (NIGMS), which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00608322's enrollment target sits among peer trials
49 1860th of 2000 higher than 139 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02704858 · 49 participants · Phase 1
Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma
- NCT03516708 · 49 participants · Phase 1
Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer
- NCT03692429 · 49 participants · Phase 1
alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells
- NCT04329494 · 49 participants · Phase 1
PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia